Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
Tel: +44 (0)1273 434 943
Email: [email protected]
NICE has today announced that EYLEA (aflibercept solution for injection, known in the scientific literature as VEGF Trap-Eye) is recommended for the treatment of patients with wet age-related macular degeneration (wAMD). EYLEA is the first new medicine in ophthalmology to be fast tracked to Final Appraisal Determination (FAD), without the need for additional consultation. This decision means that eligible patients in England and Wales, who have been newly diagnosed or have not responded well to other medicines, will now have more choice in their wAMD treatment. EYLEA has been shown in two clinical studies to work as well as current treatment,
---------------------------
This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.